Kornimate/medical-research-clean huggingface dataset:
reducing college student drinking by integrating self-affirmation and implementation intentions

Conditions: Alcohol Drinking

Summary: two hundred and ninety-three college students who reported drinking in the past month were randomly assigned to condition in a 2 (self-affirmation: values vs. control writing task) x 2 (implementation intentions: formed vs. not formed) between-subjects factorial design. participants first completed a self-affirmation or control writing task, then read an article describing the risks of drinking. next, all participants reported their common drinking behaviors and contexts, and then selected two harm-reduction strategies making either general intentions to use the strategies or making implementation intentions to use the strategies. alcohol consumption was measured 1 and 2 weeks after the experimental session.


Eligibility criteria:
inclusion criteria: * must have reported drinking at least 1 drink in the last 30 days at time of first participation. exclusion criteria: -
candidemia in critically ill patients

Conditions: Sepsis

Summary: candidal sepsis (candidemia) is a criticals problem in patients hospitalized in the intensive care unit, with a significant impact on morbidity and mortality. risk factors for candidemia in intensive care patients included age, presence of a central venous catheter, inpatient surgery, and administration of parenteral nutrition (tpn). mortality in patients with candidemia is estimated at 50-60%. early identification and treatment, including control of the source of infection, are essential to improve morbidity and mortality in these patients. in this study, we would like to identify risk factors for the development of candidemia in intensive care patients, including those who have not undergone abdominal surgery, and to examine what percentage of patients who developed candidemia were given empirical antifungal therapy and what factors influenced the decision to give or not to give such empirical therapy. study design: a retrospective study based on data collection from computerized systems will include patients who were hospitalized in the intensive care unit from january 2014 to december 2024 and were diagnosed with candida in at least one blood culture.


Eligibility criteria:
inclusion criteria: patients admitted to the icu from january 2014 to december 2024 and had at least one positive blood culture for candidemia - exclusion criteria: missing data -
potentiation of trauma exposure in post-traumatic stress disorder by repeated transcranial magnetic stimulation

Conditions: Stress Disorders, Post-Traumatic

Summary: the aim of this study is to assess the efficacy in ptsd treatment of concomitant voluntary reactivation of personal traumatic memories with neuromodulation of the right dorsolateral prefrontal cortex using 10hz rtms, compared to 1hz rtms, during 2 weeks.

post-traumatic stress disorder (ptsd) is characterized by intrusive and persistent memory of past result from an event causing or able to cause death, be a threat of death, a severe injury or constitute a threat for physical integrity. it is a frequent disorder in general population (8%). in france, the most frequent traumatic events causing ptsd are serious accidents, rape, physical assaults, violence, etc. ptsd treatment involves antidepressant and cognitive and behavioural psychotherapy, which encourage exposure to elements that remind the trauma (memories, circumstances), with the objective of reducing the fear associated with the traumatic memories. innovative therapeutic strategies aim to improve the psychotherapeutic effect with enhancement drugs or using neuromodulatory techniques, such as repeated transcranial magnetic stimulation (rtms). the aim of this study is to assess the efficacy in ptsd treatment of concomitant voluntary reactivation of personal traumatic memories with neuromodulation of the right dorsolateral prefrontal cortex using 10hz rtms, compared to 1hz rtms, during 2 weeks.

Eligibility criteria:
inclusion criteria: * pcls score \>40 * able to give his written informed consent * not participating another study * affiliation to a social security system * having a ptsd for 3 months * no treatment modification for 4 weeks (psychotropic treatment or structured psychotherapy) exclusion criteria: * partially deaf with equipment * people with identified neurological disease * people with addiction to psychoactive substance * people who can't conform to tests * people having a contraindication for rtms (cochlear implant ) * people suffering from chronicle or acute delusional disorder * any circumstances making the people unable to understood nature, aim or consequences of the study.

Keywords: stress disorders, post-traumatic trauma exposure repeated transcranial magnetic stimulation
examination of the prevention and treatment modalities of alveolitis in relation with impacted teeth surgery

Conditions: Alveolitis of Jaw; Alveoli, Teeth; Inflammation; Dry Socket; Impacted Third Molar Tooth

Summary: in the everyday clinical practice the incidence of minor complications is approximately 15-20% of the total number of third molar removals. alveolitis (dry socket syndrome) may arise in 30-40% of the surgical tooth removals. several preventive approaches are known, such as the use of iodoform gauze, zink-oxide eugenol paste, platelet rich fibrin (prf), different medicine containing pastes, like antibiotics containing, non-steroid pain killer containing, steroid containing, or the application of chlorhexidine gel and solutions. in the case of a manifest alveolitis these methods can be used as well. the aims of this research are: i) to identify the important pathogens which play role in the development of alveolitis (microbiological methods), ii) to analyze the in vitro effectivity of the different antiseptic materials in case of infections (inhibitory zones) iii) to compare the effectivity of different alveolitis preventive methods in a prospective clinical study, iv) to compare the different treatment options in alveolitis in a prospective clinical study.


Eligibility criteria:
inclusion criteria: * pell-gregory ii/b impaction * mesioangular impactions * tooth sectioning is not necessary for removal * without local infection of third molar exclusion criteria: * no general diseases or following treatments (dm, steroids, bleeding risk, chemotherapy, radiotherapy, bisphosphonates, immunosuppressive conditions)

Keywords: alveolitis iodoform chlorhexidine minor complications
effectiveness of compression stocking on overnight fluid shift in obstructive sleep apnoea patients

Conditions: Obstructive Sleep Apnea

Summary: overnight rostral fluid shift is one of the contributing factors for worsening obstructive sleep apnoea (osa). fluid shift has been recognized to play a role in the pathophysiology of sleep apnoea. previous studies shown that fluid from the leg redistributes to the neck at night increases the neck circumference, hence indicating fluid accumulation in the neck. osa patients are more susceptible to developing upper airway narrowing in response to fluid shift from the leg to the head and neck region. previous studies were mainly done on caucasian patients. the pathophysiology of osa in caucasian patients and asian patients are different but both suffer a similar degree of osa. the investigators would like to investigate if reducing leg swelling by a simple non-invasive intervention of wearing compression stocking during the day can attenuate sleep apnoea, and whether compression stocking is generally acceptable and well-tolerated among the general osa population in asia.


Eligibility criteria:
inclusion criteria: * aged 30 years old to 65 years old. * either stop-bang score of ≥3 or epworth sleepiness scale indicating mild excessive daytime sleepiness to severe excessive daytime sleepiness (11-24 points). * has pre-existing diabetes mellitus and/or hypertension and is on medication. * ability to provide informed consent. * not working night shift. exclusion criteria: * significant arterial disease due to the risk of limb ischaemia and necrosis. * not pregnant and not planning to get pregnant before the end of the study. * history of psychiatric disease. * patient who are on wheelchair. * patient who has cardiac failure and or stroke. * patient who has end-stage renal failure. estimated glomerular filtration rate \<15ml/min/1.73m2 or on renal replacement therapy i.e. dialysis or renal transplant. * patient who has liver disease. * patient who are on pacemaker, and metal implants. * patient who are on cpap treatment for osa. * patient who are illiterate. * medications which affect fluid balance or level of consciousness (e.g. diuretics, non- steroidal anti-inflammatory drugs (nsaids), corticosteroids, sedatives, opiates) at any time during the study.
esketamine combined pregabalin and duloxetine for postherpetic neuralgia

Conditions: Postherpetic Neuralgia

Summary: to assess the 1-week effects and safety of esketamine in combination with pregabalin and duloxetine to relieve pain in patients with postherpetic neuralgia(phn).

the investigators aim to investigate whether or not esketamine combined with pregabalin and duloxetine to relieve pain in patients with phn, and seek a rapid, effective and safe treatment for refractory patients with phn

Eligibility criteria:
inclusion criteria: 1. ages more than 18 years; 2. pain present for more than 3 months after healing of a herpes zoster skin rash; 3. has an average pain score of at least 4 on a numeric rating scale (nrs, 0= no pain, 10= worst possible pain)； 4. failed to respond to or tolerate the effective dose of pregabalin monotherapy. exclusion criteria: 1. obstructive sleep apnoea syndrome; 2. those who receive interventional treatments; 3. a history of systemic immune diseases, organ transplantation, or cancers; 4. a history of severe cardiopulmonary, hepatic or renal dysfunction; 5. a history of schizophrenia, epilepsy, or myasthenia gravis, delirium; 6. currently using monoamine oxidase inhibitors (maois); 7. having untreated angle-closure glaucoma; 8. those suffering from increased intracranial pressure； 9. comorbid hyperthyroidism or phaeochromocytoma; 10. suspected or confirmed history of drug abuse; 11. having contraindications to esketamine, pregabaline or duloxetine; 12. communication difficulties; 13. women who are preparing for pregnancy, in the pregnancy or lactation period.

Keywords: postherpetic neuralgia esketamine
the effects of video training given to individuals with type 2 diabetes

Conditions: Diabetes Mellitus, Type 2; Training

Summary: the goal of this randomised control type of study is to examine the effects of video diabetes training given to individuals with type 2 diabetes through smartphones on self-care and metabolic control. the hypotheses of the study: h1: video diabetes training given to individuals with type 2 diabetes through smartphones has a positive impact on individuals' self-care. h2: video diabetes training given to individuals with type 2 diabetes through smartphones has a positive impact on individuals' metabolic control variables. participants will answer the data collection tools in the first and second interviews and metabolic control variables will be record. diabetes training videos will sent to the training group through smartphones after the first meeting as two episodes a week. video diabetes training given to training group will be examine the effects of on self-care and metabolic control.

the study will conduct to examine the effects of video diabetes training given to individuals with type 2 diabetes through smartphones on self-care and metabolic control. this experimental, randomized, and controlled study will conduct with a total of 112 individuals with type 2 diabetes (56 in the training group, and 56 in the control group), who apply to the internal medicine clinic of a state hospital in the mediterranean region of turkey between february and august 2022, who volunteered to participate in the study and met the inclusion criteria. a total of 112 individuals with type 2 diabetes, who volunteered to participate in the study, and met the inclusion criteria, will select with the simple random sampling method and will randomize with the help of a computer program. participants will answer the data collection tools in the first and second interviews and metabolic control variables will be record. diabetes training videos will sent to the training group through smartphones after the first meeting as two episodes a week. video diabetes training given to training group will be examine the effects of on self-care and metabolic control.

Eligibility criteria:
inclusion criteria: * agreed to participate in the study voluntarily, * were diagnosed with type 2 diabetes for at least 6 months, * were 18 years of age or older, * were literate, had smartphones with video playback features and internet, * without a physician diagnosis that would prevent communication, and psychiatric problems and hearing problems * those who did not have sensory losses such as vision or hearing. exclusion criteria: -individuals who did not meet the inclusion criteria.

Keywords: diabetes training, metabolic control variables self-care type 2 diabetes video training
study comparing 2 different strategies for management of subjects with plaque psoriasis who have responded to etanercept

Conditions: Psoriasis

Summary: this study proposes to compare 2 different methods for managing a subject with psoriasis who has achieved good disease control, as defined by a clinical response with a physician global assessment (pga) inferior or equal to 1 at the screening visit, on etanercept treatment. the first method involves stopping etanercept treatment on entry into the study, with the option to reinitiate etanercept at 50 mg once weekly after medical review and agreement between the subject and the investigator. the second method involves continuing on etanercept at 25 mg once weekly, with the option to increase the dose to 50 mg once weekly after medical review and agreement between the subject and the investigator. subjects will be randomized into one of these two study arms.


Eligibility criteria:
inclusion criteria: * eighteen (18) years of age or older at the time of consent. * previously treated with etanercept for chronic plaque psoriasis for at least 12 weeks prior to the screening visit and received a total weekly dose of 50 mg per week for at least the 6 weeks preceding the day of the screening visit * having shown clinical response with a pga inferior or equal to 1 at the screening visit. * pga inferior or equal to 1 at the baseline visit. exclusion criteria: * evidence of skin conditions (eg, eczema) other than psoriasis that would interfere with evaluations of the effect of study medication on psoriasis. * evidence of active or previously known medical history of inflammatory arthritis (eg, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis). * any biologics other than etanercept within the 20 weeks prior to the screening visit.

Keywords: plaque psoriasis - etanercept - response maintenance
transbronchial cryobiopsy in lung transplant patients

Conditions: Lung Transplantation

Summary: cryobiopsy has displaced the transbronchial biopsy (btb) with forceps because it allows to obtain samples of more representative pulmonary parenchyma with more alveoli, less artifacts and a greater diagnostic yield. however, some authors report an increase in adverse effects such as hemorrhage and pneumothorax. the latest ishlt (international society for heart and lung transplantation) consensus of 2007 recommends that with btb with forceps a minimum of five tissue samples should be obtained that should contain more than 100 wells or the presence of two bronchioles to which may be necessary between 3 and 17 samples. the optimal number of transbronchial cryobiopsies is unknown in order to obtain maximum performance with the lowest possible morbidity. it is proposed to analyze the morphological and histopathological characteristics of each cryobiopsies individually and in order of extraction, to determine the sensitivity in the diagnosis of acute rejection as a function of the number of samples. lung transplant patients, not admitted to critical units, with btb indication will be included. a maximum of 6 samples will be obtained by flexible bronchoscope and under general anesthesia. these data will allow to know the minimum number of specimens that guarantee a histological and / or bacteriological diagnosis of certainty with maximum effectiveness.

transbronchial biopsies (bptb) will be performed using a flexible bronchoscope and the biopsy will be performed with cryoprobe (erbokryo®). the patient undergoing the procedure will be intubated, sedated and relaxed under continuous monitoring (pulse oximetry, blood pressure, heart and respiratory rate), oxygen therapy with high flows and surveillance by anesthesiologist. the site where the biopsies will be performed will be determined based on an imaging study (chest x-ray and / or ct scan). the procedure will be performed according to the conventional technique, keeping the patient in apnea during the time that the cryobiopsies are taken to reduce the risk of pneumothorax. at most 6 samples will be obtained, and each one will be placed in an individual container listed in order of extraction. bronchoalveolar lavage (3 aliquots of 30 ml sterile saline solution) will be performed in the same hemithorax. the samples obtained will be evaluated morphologically and sent to a microbiological and histopathological study, which will include a cell count. the data obtained will be coded.

Eligibility criteria:
inclusion criteria: * pulmonary transplant patients with suspected rejection or infection requiring transbronchial biopsy exclusion criteria: * respiratory failure refractory to oxygen therapy. * acute or subacute ischemic heart disease (last 4-6 weeks). * severe arrhythmias. * coagulation disorders: platelets \<60,000-50,000 or prothrombin time \<60%. * lack of consent informed.

Keywords: cryoprobe bronchoscopy acute cellular rejection
pembrolizumab (mk-3475) plus epacadostat vs standard of care in mrcc (keynote-679/echo-302)

Conditions: Renal Cell Carcinoma (RCC)

Summary: the purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat compared to sunitinib or pazopanib in participants with locally advanced/metastatic renal cell carcinoma (mrcc) with a clear cell component who have not received prior systemic therapy for their mrcc.


Eligibility criteria:
inclusion criteria: * histologic confirmation of locally advanced or metastatic rcc with a clear-cell component with or without sarcomatoid features. * must not have received any prior systemic therapy for their mrcc. * measurable disease based on recist v1.1. * archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion as required. * karnofsky performance status ≥ 70%. * adequate organ function per protocol-defined criteria. exclusion criteria: * use of protocol-defined prior/concomitant therapy. * currently receiving or has received an investigational treatment as part of a study of an investigational agent or has used an investigational device within 4 weeks before randomization. * history of severe hypersensitivity reaction to study treatments or their excipients. * active autoimmune disease that has required systemic treatment in past 2 years. * known additional malignancy that has progressed or has required active treatment in the last 3 years. * known active central nervous system metastases and/or carcinomatous meningitis. * history of (noninfectious) pneumonitis that required steroids or current pneumonitis. * history or presence of an abnormal electrocardiogram that, in the investigator's opinion, is clinically meaningful. * significant cardiac event within 12 months before cycle 1 day 1.

Keywords: renal cell carcinoma programmed cell death 1 (pd-1) inhibitor indoleamine 2 3-dioxygenase 1 (ido1) inhibitor
effectiveness of interpersonal psychotherapy (ipt) for men and women prisoners with major depression

Conditions: Major Depressive Disorder

Summary: this study will examine the effects of a first-line treatment for major depressive disorder (mdd), interpersonal psychotherapy (ipt), among men and women prisoners.

the purpose of this 3-year randomized trial is to promote uptake of evidence-based treatment in criminal justice settings by conducting a fully-powered randomized effectiveness study that collects pilot implementation data, including cost-effectiveness data. group ipt will be compared to treatment as usual (tau) in a sample of 90 male and 90 female prisoners with mdd from 4 institutions, allowing us to explore gender effects.

Eligibility criteria:
inclusion criteria: * meet all dsm-iv criteria for primary (non-substance induced) major depressive disorder * expectation of at least 6 months of incarceration at baseline interview * incarcerated for at least 4 weeks exclusion criteria: * lifetime: * bipolar disorder * psychotic disorder * are imminently suicidal * cannot understand english well enough to understand the consent form or assessment instruments when read aloud

Keywords: major depressive disorder (mdd) suicidality incarcerated populations prisons interpersonal psychotherapy (ipt)
evaluate the efficacy and the tolerance of the medical device v063b-dp3003 on dentin hypersensitivity during teeth whitening

Conditions: Tooth Whitening

Summary: a dental gel intended to relieve pain related to dentin hyper sensitivity is commercialized in several countries worlwide since may 2017. its efficacy and tolerance has already been proven in dentin hyper sensitivity. in this new study, we assess the efficacy and tolerance of this tested product in a specific external agression, the teeth whitening.

comparative open-label pmcf (post-market clinical follow-up) randomized controlled study will be conducted as multicentric trial in adult with dentin hypersensitivity during their teeth whitening. to evaluate the efficacy and tolerance of the medical device elgydium clinic sensileave gel (v063b - dp3003) on dentin hypersensitivity during teeth whitening 4 visits are planned: * visit 1 (v1) - selection * visit 2 (v2) - start of teeth whitening * visit 3 (v3) - start of tested product application - inclusion / randomization * visit 4 (v4) - study end

Eligibility criteria:
inclusion criteria: * subject who has a pain score (i.e. maximum intensity felt while the whitening tray wear) of at least 3 on a nrs ranging from 0 (none) to 10 (severe) evaluated since the beginning of his teeth whitening. * subject wishing to have a teeth whitening * subject with a healthy gum status according to the investigator * subject with at least 20 natural teeth exclusion criteria: related to the teeth condition: * subject with active teeth decay * subject with teeth showing evidence of facets of attrition, premature contact, cracked enamel on the teeth to be studied and adjacent teeth * subject with teeth showing evidence of irreversible pulpitis and active periodontal disease * subject having a cutaneous-mucosal disease liable to interfere with study data according to the investigator * subject with an odontological condition, an acute chronic or progressive disease or history of disease considered by the investigator hazardous for the subject or incompatible with the study related to the treatment/product: * subject having undergone professional desensitizing therapy in the mouth * systemic treatment/product and topical treatment/product in the mouth liable to interfere with study data according to the investigator assessment